Please go to the PowerPak homepage
and select a course.
The Changing Paradigm of Rheumatoid Disease Management: Challenges and Opportunities for Specialty Pharmacists
This activity is supported by an educational grant from AbbVie Inc.
Rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondylitis (AS) are systemic autoimmune disorders characterized by chronic inflammation involving the musculoskeletal system. If left untreated or inadequately treated, these diseases can result in debilitating pain, structural damage, and significant reduction in patient quality of life. Numerous therapies, especially those within the biologic disease-modifying antirheumatic drug class, have greatly improved outcomes for patients when used as monotherapies or in combination with other immunomodulatory drugs. Many of these treatments are considered specialty medications, with complex dosing and administration regimens and harbor the potential to cause drug-related adverse events. It is essential for pharmacists to remain up to date on the latest evidence-based guidelines on the use of these medications, as well as on special considerations related to safety issues for individual drugs or classes of drugs, in order to effectively educate patients and recognize the signs of potentially harmful side effects as soon as possible.
To educate pharmacists on the pathophysiology of rheumatic diseases, current treatment options and recommendations for the treatment of rheumatic diseases, and special safety considerations related to the use of these medications.
After completing this activity, participants should be better able to:
- Describe the pathophysiologic processes of RA, PsA, and AS
- Discuss the range of pharmacotherapies available for RA, PsA, and AS
- Review the safety profiles of treatments for RA, PsA, and AS
- Define the role of specialty pharmacists in promoting patient adherence to therapies for RA, PsA, and AS
Type of Activity
Susan P. Bruce, PharmD, BCPS
Pharmacy Education and Interprofessional Studies
Chair and Professor
Northeast Ohio Medical University
In support of improving patient care, Continuing Education Alliance is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.
This program is approved for 1.5 contact hours (0.15 CEUs). Universal Activity Number JA4008073-0000-18-001-H01-P.
The opinions or views expressed in this CPE activity do not necessarily reflect the opinions or recommendations of Continuing Education Alliance or AbbVie.
All faculty and planners participating in continuing education activities sponsored by Continuing Education Alliance are expected to disclose to the audience any significant support or substantial relationships with providers of commercial products and/or devices discussed in this activity and/or with any commercial supporters of the activity. In addition, all faculty are expected to openly disclose any off-label, experimental, or investigational use of drugs or devices discussed in this activity. The faculty and planning committee have been advised that this activity must be free from commercial bias, and based upon all the available scientifically rigorous data from research that conforms to accepted standards of experimental design, data collection, and analysis.
Dr Bruce has no relevant financial relationships to disclose.
The Planning Committee for this activity included Ruth Cohen and Angela Incassati of Continuing Education Alliance. The members of the Planning Committee have no significant relationships to disclose.
How To Receive Credit
Participants wishing to earn CPE credit must:
- Read the supplement in its entirety.
- Relate the content material to the learning objectives.
- Complete the self-assessment questions and evaluation form online.
The estimated time to complete this activity is 1.5 hours.
Successful completion of the self-assessment is required to earn CPE credit. Successful completion is defined as a cumulative score of at least 70%. A certificate of credit will be automatically generated upon successful completion of the activity.
The providers of this program have waived the processing fees.
July 2, 2018
November 2, 2018
For CE Alliance general information, contact firstname.lastname@example.org.
The materials presented here do not necessarily reflect the views of Continuing Education Alliance, Practicing Clinicians Exchange, or companies that provide educational support for programming on practicingclinicians.com. These activities may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should verify all information and data before treating patients or implementing any therapies described in these educational activities. © 2018 Continuing Education Alliance and Practicing Clinicians Exchange. All Rights Reserved. Terms and Conditions.